Krebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krebs Biochemicals reported deeply negative results for Q2 and H1 FY26. Revenue from operations fell sharply to Rs. 416.74 lakhs in Q2 FY26 from Rs. 548.09 lakhs a year ago, while H1 revenue crashed to Rs. 964.83 lakhs from Rs. 2,574.42 lakhs (a drop of roughly 63%). The company posted a loss before tax of Rs. 614.28 lakhs in Q2 (vs Rs. 532.43 lakhs loss last year) and Rs. 1,146.71 lakhs in H1. Net worth is deeply negative at minus Rs. 14,623.88 lakhs, and total borrowings stand at around Rs. 21,220 lakhs. The Vizag manufacturing unit remains shut since February 2025 on an Andhra Pradesh Pollution Control Board order, which explains the revenue collapse. Operating cash flow was also negative at minus Rs. 167.56 lakhs for H1.
This is a serious red flag for shareholders. With a negative net worth, a regulator-forced plant shutdown, collapsing revenues, and widening losses, the company's going concern status is in serious question. Equity investors face high risk of further value erosion; the stock is likely to remain under pressure.